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ABSTRACT
The occurrence of the two Shewanella species found in clinical specimens, Shewanella algae and Shewanella
putrefaciens, correlates with the temperature and salinity of seawater. This means that Shewanella
infections occur in warm climates or during especially warm summers in temperate climates. The
infections described most commonly involve ears, skin and soft tissue, with or without bacteraemia.
Primary bacteraemia with a fulminant course is also seen in immunocompromised patients. Important
differential characteristics between the two species include the ability of S. algae to produce mucoid
colonies with b-haemolysis on sheep blood agar, to grow at 42C and in NaCl 6% w ⁄ v, and to reduce
nitrite, and an inability to produce acid from maltose, all of which are in contrast to the characteristics of
S. putrefaciens. Automated identiﬁcation systems fail to differentiate between S. algae and S. putrefaciens,
as S. algae is not included in the databases of these systems. Presumably for this reason, most Shewanella
infections reported during recent years have been attributed to S. putrefaciens. However, when extensive
phenotypic characterisation is performed, most human infections are seen to be caused by S. algae. As
the two species seem to have different pathogenic potential for humans, correct identiﬁcation is
important, and this is possible in routine clinical microbiology laboratories.
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INTRODUCTION
Human infections with members of the genus
Shewanella are rare, being reported mainly from
geographical areas with warm climates, e.g., the
USA [1–8], Australia [9–13], Asia [14–22], South
Africa [23,24] and southern Europe [25–30]. How-
ever, in recent years, cases from countries with
temperate climates have also been reported [31–
33]. Although the clinical signiﬁcance of these
organisms has often been obscured by their
occurrence as part of a mixed bacterial ﬂora, a
number of monomicrobial infections have been
reported, thereby documenting the pathogenic
potential of Shewanella spp. [1,6,12,14,15,24,25,
28–31].
Since the publication of Nozue et al. [34], it has
become increasingly clear that most reports of
human infections attributed to Shewanella putre-
faciens have been caused by the species now
named Shewanella algae [34–36]. Despite this, most
infections caused by Shewanella spp. that have
been reported in the literature have been attrib-
uted to S. putrefaciens [9,11,12,14,15,17,30]. This
review describes the characteristics of S. algae and
S. putrefaciens, and the bacteriological and clinical
differences between these two species.
HISTORY AND TAXONOMY
Shewanella spp. are Gram-negative, motile bacilli,
whose most important phenotypic characteristic
is the production of hydrogen sulphide. The ﬁrst
description of the species was provided in 1931 by
Derby and Hammer [37], who isolated a hitherto
unknown bacterial taxon from putreﬁed butter
and water supplies of dairies, and named it
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Achromobacter putrefaciens. In 1941, Long and
Hammer [38] proposed that this species should
be transferred to the genus Pseudomonas under the
name Pseudomonas putrefaciens. During the next
three decades, these organisms were placed in
Pseudomonas group IV, according to Shewan et al.
[39], and they became known as some of the most
important spoilage bacteria of ﬁsh [40–43].
In the 1974 edition of Bergey’s Manual of
Systematic Bacteriology, P. putrefaciens was classi-
ﬁed as ‘species incertae sedis’, mainly because the
G + C content of 43–55% was below the range for
Pseudomonas spp. (58–70%). However, several
studies agreed that isolates of P. putrefaciens could
be separated into at least two different taxa on the
basis of differences in salt tolerance, growth
temperatures and saccharolytic activity [44–46].
In 1978, Owen et al. [47] divided isolates into four
DNA homology groups, I–IV, a division that
supported the results of other investigators
[34,36,48]. In 1985, phylogenetic studies resulted
in a reclassiﬁcation of these organisms to the
family Vibrionaceae, and the description of a new
genus, Shewanella [49], named after James Shewan
in honour of his work in marine microbiology.
Included in this new genus was S. putrefaciens and
the related species Shewanella hanedai and Shewa-
nella benthica.
In the early 1990s, DNA homology group IV of
Owen et al. [47] was reclassiﬁed as a new species,
Shewanella alga (sic), by Simidu et al. [50], emen-
ded subsequently by Nozue et al. [34] on the basis
of genomic and phenotypic studies. S. alga was
found to have a G + C content of 52–54 mol%,
compared with 46% for the type strain of
S. putrefaciens, while DNA homology between
the type strains of S. alga and S. putrefaciens was
found to be < 10%. Other studies conﬁrmed the
signiﬁcant genomic differences between the two
species by ribotyping, 16S rRNA analysis, gyrB
gene sequencing, and DNA–DNA hybridisation
[36,51]. In 1997, the name of this new species was
corrected to S. algae [52]. On the basis of small-
subunit rDNA sequencing, the genus Shewanella
was shown to be a robust monophyletic taxon
within the gamma subgroup of the phylum
Proteobacteria [53]. Recent results of 16S rRNA
gene sequence analyses of genera from this group
led to a proposal for a new family, Shewanella-
ceae [54], containing about 30 Shewanella spp.,
most of which are psychrophilic and therefore of
little interest to clinical microbiologists.
EPIDEMIOLOGY AND
PATHOGENICITY
Shewanella spp. are found throughout the world,
mainly in marine environments. They are import-
ant in the turnover of organic material, and are
capable of dissimilatory reduction of various
metals and other substances, such as nitrate,
nitrite, thiosulphate and trimethylamine-N-oxide.
In Denmark, S. putrefaciens and S. algae can be
isolated from seawater with a salinity of 15–20%
[32], with the frequency of occurrence being
correlated with the temperature of the seawater
[55]. These organisms are detected in Denmark
only during the months of July–October, when
the water temperature is > 13C [55]. This obser-
vation accords with the fact that most Shewanella
infections occur in countries with a warm climate,
or during especially warm summers in countries
with temperate climates.
The only Shewanella spp. found in clinical
specimens are S. putrefaciens and S. algae, and it
seems likely that > 80% of isolates from humans
are S. algae [32,34–36]. Of 164 clinical isolates
examined by Holt et al. [56], mostly from ear
swabs, only ﬁve were identiﬁed as S. putrefaciens.
As these organisms are frequently isolated to-
gether with other bacteria, the pathogenic poten-
tial of Shewanella has been controversial. In a
study of mice in which 1 mL of seawater was
inoculated into surgical wounds, 30% of the mice
developed a wound infection from which
‘P. putrefaciens’ isolates were cultured. Three of
these isolates were then inoculated intraperiton-
eally into rats. This procedure resulted in bacter-
aemia in three of ten rats, with an LD50 of 50%
[57]. It is not known whether the isolates used
were S. algae or S. putrefaciens. Saxe and Levin [58]
found no difference in pathogenicity between
strains of S. putrefaciens ‘biotype I’ and ‘biotype II’
(equivalent to S. algae). However, another mouse
pathogenicity study performed by Khashe and
Janda [35] indicated that S. algae was the more
virulent species, and it was speculated that the
haemolytic activity of S. algae could be an import-
ant virulence factor [35]. An ability to form
bioﬁlms has been described in detail for Shewa-
nella oneidensis and S. putrefaciens [59,60]. In a
Danish study of ear infections involving S. algae,
49% of patients had ear tubes, and bioﬁlm
formation could be a pathogenicity factor in such
cases [32]. S. algae is tolerant to bile salts, and
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produces extracellular virulence factors such as
siderophores and other exoenzymes [61]. Produc-
tion of tetrodotoxin, the pufferﬁsh toxin, has been
reported [50], but this ﬁnding could not be
reproduced by other investigators [61,62]. Intra-
peritoneal inoculation in mice has given rise to
speciﬁc antibodies against S. putrefaciens [63].
The most obvious source for human infection is
exposure to seawater. Such contact has been
reported in some of the case reports in the
literature [5,8,11,15,16,31,56] and in a Danish
study of ear infections, where > 80% of patients
had been swimming in the sea shortly before
symptoms developed [32]. In Denmark, environ-
mental and clinical isolates of S. algae demonstrate
great clonal variability, as determined by ribo-
typing and random ampliﬁed polymorphic DNA
proﬁling, but no systematic differences distin-
guishing environmental and clinical isolates have
been found [64]. Furthermore, a Danish seawater
isolate was found to be identical to one of the
clinical isolates by all typing methods [64], sup-
porting the theory of a marine source of infection.
PHENOTYPIC CHARACTERISATION
AND IDENTIFICATION
S. algae and S. putrefaciens are non-fermentative
bacilli with a single polar ﬂagellum. They grow
well on conventional solid media, including Mac-
Conkey agar, with 1–2-mm yellowish-brown col-
onies after incubation for 18–24 h. Table 1
summarises the main differences between S. algae
and S. putrefaciens found by different investigators
[32,34–36,50,56,65]. Characteristic traits include
production of hydrogen sulphide, decarboxylation
of ornithine, and hydrolysis of gelatine. S. putre-
faciens is the more saccharolytic of the two species,
with S. algae producing acid only from ribose, and
sometimes from glucose and fructose, while
S. putrefaciens produces acid from maltose and
glucose, and sometimes sucrose and arabinose. In
contrast to S. putrefaciens, S. algae shows weak
b-haemolysis on sheep blood agar after incubation
for 48 h, as well as growth at 42C and in NaCl 6%
w ⁄ v. Holt et al. [32,56] also found that S. algae was
distinguished from S. putrefaciens by a mucoid
colony consistency and an ability to reduce nitrite.
Automated identiﬁcation systems are unable to
distinguish between S. putrefaciens and S. algae.
A large number of clinical isolates identiﬁed
tentatively as S. putrefaciens were shown to be
S. algae by Nozue et al. [34]. A number of reports
of human infections allegedly caused by S. putre-
faciens do not supply sufﬁcient data to show
whether or not the isolates were actually S. algae
[9,11,12,14,15,17,30]. This problem is caused by
the fact that the semi-automated and automated
identiﬁcation systems used for identiﬁcation in
these reports (API 20E and 20NE; API ID 32 GN
and Vitek) include S. putrefaciens, but not S. algae,
in their databases. It also appears that these
identiﬁcations as S. putrefaciens were not con-
ﬁrmed by reference laboratories.
CLINICAL MANIFESTATIONS
The clinical syndromes reported to be caused by
S. algae and S. putrefaciens (hereafter called Shewa-
nella infections unless the species designation is
clearly justiﬁed) are generally the same as those
caused by various species of the other marine
halophilic genus Vibrio [11,66,67].
In Denmark, the most common Shewanella
infection is infection of the ear with S. algae. This
can take the form of acute infection or acute
exacerbation in chronic otitis media in predis-
posed individuals. In a study of 67 ear infections
Table 1. Summary of biochemical characteristics of Shewa-
nella algae and Shewanella putrefaciens (type strains and
results taken from different studies [32,34–36,50,56,66])
S. algaeT
(IAM 14159) S. algae
S. putrefaciensT
(ATCC 8071) S. putrefaciens
Oxidase + + + +
Catalase + + + +
Indole production – – – –
Arginine dihydrolase – – – –
Lysine decarboxylase – – – –
Ornithine decarboxylase + + + +
H2S production + + + +
Urea hydrolysis – – – –
Gelatine hydrolysis + + + +
DNA hydrolysis + + + +
Nitrate reduction + + + +
Nitrite reduction + + – –
Acid from
Arabinose – – + d
Ribose (+) (+) + d
Glucose (+) (+) + d
Fructose ()) (+) – d
Mannitol – – – –
Lactose – – – –
Maltose – – – d
Sucrose – – – d
Growth
4C – – + +
42C + + – –
NaCl 6–6.5% w ⁄v + + – –
Haemolysis
(sheep blood, 48 h)
+ + – –
Mucoid colony
consistency
+ + – –
Parentheses indicate delayed ⁄weak reactions; d, variable results.
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[32], all Shewanella infections were caused by
S. algae, with this organism being isolated in pure
culture in 50% of cases. Outside Denmark, only a
few such ear infections have been reported, and
these date from the 1970s [2–4,22,44].
The most common clinical syndrome described
in the literature is infection of skin and soft tissue,
associated with breaches in the skin such as ulcers
or following trauma [10,11,15,16,24,30,31,68,69].
Bacteraemia is often present, but the course is
usually benign. In approximately 40 published
reports, c. 40% of cases have involved pure
cultures of Shewanella. Two cases of S. alga (sic)
bacteraemia, one with myonecrosis, involving
patients with chronic ulcers have been reported
in Denmark [31]. Primary bacteraemia, associated
with severe hepatobiliary disease and malignancy
with an often fulminant course, has also been
described [6,16,24]. A distinction between these
two syndromes is not always possible, as cases
involving both cellulitis and underlying debilita-
ting diseases have been described.
Another clinical syndrome, hitherto described
only in South Africa, is paediatric bacteraemia in
underweight babies [24], with 19 cases occurring
in two hospitals during 1990–1993. Of 16 neo-
nates, all suffered from respiratory distress at
birth, and six subsequently died. In 12 cases, the
organism was isolated shortly after birth, thereby
indicating the possibility of intrapartum infection.
Respiratory colonisation, and possibly infec-
tion, has been seen in a peritoneal dialysis patient
with bacteraemia [13], in a patient after near-
drowning [8], in patients with tuberculosis [70],
and in patients with pleural empyema as a
complication of biliary tract infection [16]. There
are also anecdotal reports of Shewanella bone and
joint infections [2,7,10,28], meningitis [26], cere-
bellar abscess [14], endocarditis [17], an infected
aortic aneurysm [29] and eye infections [1,16].
Among the clinical isolates examined by Holt
et al. [56], only 3%were identiﬁed as S. putrefaciens.
The organism was not detected in blood cultures,
and evidence of its pathogenic role in Danish
clinical cases is lacking. This is in agreement with
the ﬁndings of other investigators [34–36].
ANTIBIOTIC SUSCEPTIBILITY AND
TREATMENT
S. algae and S. putrefaciens are characteristically
susceptible to aminoglycosides, carbapenems,
erythromycin and quinolones, but resistant to
penicillin [6,16,32,36,45,56]. Susceptibility to
ampicillin and cephalosporins is variable, with
more isolates being susceptible to third- and
fourth- than to ﬁrst- and second-generation
cephalosporins [6,32,45,56]. All Danish S. algae
isolates were susceptible to piperacillin, amino-
glycosides, ciproﬂoxacin, erythromycin and tet-
racycline, while susceptibility to ampicillin and
cephalosporins varied [56]. All isolates of S. algae
were resistant to colistin, while six clinical iso-
lates of S. putrefaciens were all susceptible. Thus
polymyxin susceptibility can be used to differen-
tiate between the two species. The six cases
involving S. putrefaciens were regarded as coloni-
sations and were consequently not treated with
speciﬁc antibiotics. In contrast, many cases with
S. algae were treated with local or systemic
antibacterial agents [32,56]. According to the
literature, most Shewanella infections are treated
easily by a combination of surgical therapy ⁄drain-
age and antibiotics [14,15,29,31,32,56,69]. Poor
outcome is associated most often with under-
lying disease [6,16,24]. Treatment options include
b-lactams (provided that the strain is susceptible),
aminoglycosides and quinolones.
CONCLUSIONS
The increasing number of reports of Shewanella
infections in which the organism has been isola-
ted in pure culture indicates the pathogenic
potential of this genus. Most human infections
are caused by S. algae. Automated identiﬁcation
systems are unable to distinguish between
S. putrefaciens and S. algae. Important differences
between the two species exist regarding genotypic
and phenotypic characteristics, pathogenicity and
susceptibility to antimicrobial agents. A prere-
quisite for further study in this ﬁeld is correct
identiﬁcation, which is possible in routine clinical
microbiological laboratories with careful conven-
tional phenotypic characterisation.
The epidemiology and clinical symptoms of
S. algae infections are similar to those of infec-
tions involving Aeromonas and halophilic Vibrios.
The most common S. algae infections involve
ears and soft tissue, but serious infections such
as bacteraemia, meningitis and endocarditis
have also been described. Marine environments
can often be implicated as the source of infec-
tion.
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